-
Tytuł:
-
Early Outcomes of Patients With Locally Advanced Non-small Cell Lung Cancer Treated With Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiation Therapy: The Mayo Clinic Experience
-
Autorzy:
-
Nathan Y. Yu, MD
Todd A. DeWees, PhD
Chenbin Liu, PhD
Thomas B. Daniels, MD
Jonathan B. Ashman, MD, PhD
Staci E. Beamer, MD
Dawn E. Jaroszewski, MD
Helen J. Ross, MD
Harshita R. Paripati, MD
Jean-Claude M. Rwigema, MD
Julia X. Ding
Jie Shan, MS
Wei Liu, PhD
Steven E. Schild, MD
Terence T. Sio, MD, MS
-
Temat:
-
Medical physics. Medical radiology. Nuclear medicine
R895-920
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
-
Źródło:
-
Advances in Radiation Oncology, Vol 5, Iss 3, Pp 450-458 (2020)
-
Wydawca:
-
Elsevier, 2020.
-
Rok publikacji:
-
2020
-
Kolekcja:
-
LCC:Medical physics. Medical radiology. Nuclear medicine
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
-
Typ dokumentu:
-
article
-
Opis pliku:
-
electronic resource
-
Język:
-
English
-
ISSN:
-
2452-1094
-
Relacje:
-
http://www.sciencedirect.com/science/article/pii/S2452109419301125; https://doaj.org/toc/2452-1094
-
DOI:
-
10.1016/j.adro.2019.08.001
-
Dostęp URL:
-
https://doaj.org/article/432556d22f9544dda3f073ca3d3e6fdb  Link otwiera się w nowym oknie
-
Numer akcesji:
-
edsdoj.432556d22f9544dda3f073ca3d3e6fdb
-
Purpose: There are very little data available comparing outcomes of intensity-modulated proton therapy (IMPT) to intensity-modulated radiation therapy (IMRT) in patients with locally advanced NSCLC (LA-NSCLC). Methods: Seventy-nine consecutively treated patients with LA-NSCLC underwent definitive IMPT (n = 33 [42%]) or IMRT (n = 46 [58%]) from 2016 to 2018 at our institution. Survival rates were calculated using the Kaplan-Meier method and compared with the log-rank test. Acute and subacute toxicities were graded based on Common Terminology Criteria for Adverse Events, version 4.03. Results: Median follow-up was 10.5 months (range, 1-27) for all surviving patients. Most were stage III (80%), received median radiation therapy (RT) dose of 60 Gy (range, 45-72), and had concurrent chemotherapy (65%). At baseline, the IMPT cohort was older (76 vs 69 years, P